Although the strategic rationale for combining Boston Scientific and Guidant appears compelling, we have lingering concerns.
We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.
We believe that Boston Scientific can raise its offer to $78 a share and still maintain an investment-grade credit rating.